John Kelly summarizes a recent paper published in JAMA that describes the benefits of robotic surgery versus open cystectomy.

Cora Sternberg, MD, discusses her career that has spanned multiple continents.

Syed Hussein and Sam Funt describe their studies on this topic.

Matt Galsky and Tom Powles take the FDA and EMA approach respectively concerning adjuvant nivolumab for bladder cancer.

Cisplatin-based combination chemotherapy is considered standard of care in mUC, but many patients are deemed ineligible.

Dr. Jonathan Rosenberg describes the results of this positive randomized phase 2 trial.

Dr. Joaquim Bellmunt gives an overview of the updated ESMO guidelines on bladder cancer.

Jonathan Rosenberg discusses what happened in the world of bladder cancer during 2021 and what to look out for in 2022.

Dr. Arjun Balar discusses bladder cancer, clinical trials involving pembrolizumab, and his career transition.

Dr. Sarmad Sadeghi discusses exciting data about a novel compound in urothelial cancer with Brian and Tom.

Dr. Jonathan Rosenberg gives an overview of the NORSE Study.

Dr. Dean Bajorin discusses developments in bladder and collaboration in testis cancer.

Dr. Ashish Kamat walks through ongoing issues around surgery in urothelial cancer at EAU 2021.

Join the debate around pembrolizumab monotherapy in initial treatment of cisplatin-ineligible metastatic urothelial cancer.

Matt Gowski takes a deeper dive into the phase 2 data of neoadjuvant chemo/nivolumab in muscle-invasive bladder cancer.

The Uromigos and Andrea Necchi have a wide-ranging discussion of 3 interesting neoadjuvant IO-based phase 2 trials.

Arjun Balar explains why, despite a negative trial, T cell stimulation plus checkpoint inhibition may warrant future study.

Dr. Lydia Makaroff, Vice President of the World Bladder Cancer Patient Coalition, discusses key issues for bladder cancer.

Dr. Petros Grivas discusses the accelerated approval of sacituzumab govitecan in bladder cancer.

Dr. Andrea Apollo discusses highlights from the ODAC meeting regarding accelerated approvals for bladder cancer.